source
- FDA advisory panel finds Grail's Galleri multicancer blood test benefits outweigh risksA Food and Drug Administration advisory panel voted 7-2, with one abstention, to conclude that the probable benefits of Grail's Galleri multicancer blood test outweigh its risks. The panel unanimou…
- Merck's remigromig meets visual acuity goal in diabetic macular edema trial, safety signals notedMerck announced that its experimental eye drug remigromig achieved non‑inferiority to Roche’s Lucentis in a late‑stage trial for diabetic macular edema. The trial, called Brunello, measured visual…